stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio clinico randomizzato di fase II, in aperto, di non inferiorità che studia il mantenimento con NiraParib dopo 3 vs. 6 cicli di chemioterapia a base di platino in pazienti con carcinoma ovarico di alto grado in stadio avanzato, HRDpositivo e dopo citoriduzione chirurgica completa di prima linea

Stato
Autorizzato - In attesa di apertura
Codice studio
ENGOT-ov62/ NOGGO-ov53/ N-Plus
Codice EudraCT
2022-502559-69-01
Sponsor/Promotore
NOGGO e.V.
Tipologia
Sperimentale
Fase
II
Unità Operativa
Oncologia 2
Principal Investigator

Studio REal-world sull’efficacia e la sAfety della combinazione pembroLizumab-lenvatInib, in pazienti con carcinoma endomeTriale avanzato trattati in ItalYa (REALITY)

Stato
Autorizzato - In attesa di apertura
Codice studio
REALITY
Codice EudraCT
NP
Sponsor/Promotore
Istituto di Ricerche Farmacologiche 'Mario Negri' - Milano
Tipologia
Osservazionale
Fase
.
Unità Operativa
Oncologia 2
Principal Investigator

Valutazione degli outcomes (esiti clinici) nelle pazienti con carcinoma ovarico avanzato in base allo stato di Ricombinazione Omologa e terapie abbinate in uno scenario di real-world. Uno studio retrospettivo e prospettico, multicentrico, a due coorti

Stato
Autorizzato - In attesa di apertura
Codice studio
BeLIVE
Codice EudraCT
NP
Sponsor/Promotore
Consorzio Oncotech
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Akynzeo come trattamento antiemetico in pazienti con carcinoma dell’endometrio trattati con chemioterapia combinata taxano – platino. Studio NOEME

Stato
Aperto - reclutamento in corso
Codice studio
NOEME
Codice EudraCT
2023-504150-35-00
Sponsor/Promotore
Istituto Nazionale Tumori - Milano
Tipologia
Sperimentale
Fase
IV
Unità Operativa
Principal Investigator

A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of hrd positive ovarian tumours (IOLANTHE)

Stato
Aperto - reclutamento in corso
Codice studio
IRFMN-OVA-8542 (IOLANTHE)
Codice EudraCT
2022-502242-27-00
Sponsor/Promotore
YMaGiNe (Young MaNGO Gynecologic Network)
Tipologia
Sperimentale
Fase
IV
Unità Operativa
Principal Investigator

Trattamento con Olaparib oltre la progressione confrontato con chemioterapia a base di platino dopo citoriduzione secondaria in pazienti con recidiva da carcinoma ovarico. MITO 35b, studio di fase 3 randomizzato: un progetto dei Gruppi MITO-MANGO.

Stato
Aperto - reclutamento in corso
Codice studio
MITO 35b
Codice EudraCT
2021-000245-41
Sponsor/Promotore
Istituto Nazionale Tumori IRCCS Fondazione 'Pascale' - Napoli
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top